Metastatic Colorectal Cancer (mCRC) Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Merck, Alexion, Array BioPharma, Eli Lilly, Taiho Oncology, Bristol-Myers Squibb, Amgen, Mirati Therapeutics

In 2021, the Metastatic Colorectal Cancer (mCRC) Market size in the 7MM was USD 12,613.9 million, which is expected to rise during the study period (2019-2032). As per DelveInsight, the Metastatic Colorectal Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Metastatic Colorectal Cancer (mCRC) and the launch of new therapies in the market.

DelveInsight's "Metastatic Colorectal Cancer (mCRC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Colorectal Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Metastatic Colorectal Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Colorectal Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Metastatic Colorectal Cancer (mCRC): An Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. Approximately one-fifth of CRC cases are metastatic at the time of diagnosis.

Metastatic CRC is still an incurable disease for most of the patients, with most commonly liver, lung or lymph nodes and peritoneal metastases. However, in the field of systemic therapy, there has been significant progress with new drugs in recent years. There are more options of initial systemic chemotherapy, oxaliplatin, irinotecan, and fluoropyrimidines, in combination with targeted therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab) in case of KRAS wild type tumors or anti-vascular endothelial growth factor (VEGF) inhibitors (monoclonal antibodies bevacizumab, aflibercept, ramucirumab, regorafenib as per oral tyrosine kinase inhibitor). The combination of these novel chemotherapies and targeted therapy now extends the mOS up to 40 months.

Metastatic Colorectal Cancer (mCRC) Market Key Facts
• The total market size of Metastatic Colorectal Cancer in the United States accounted for USD 5,155.1 million in 2021.
• In EU5, the total market size of Metastatic Colorectal Cancer was USD 4,618.5 million in 2021.
• In Japan, the total market size of Metastatic Colorectal Cancer was USD 2,840.4 million in 2021.
• In the year 2021, the total incident cases of Metastatic Colorectal Cancer were 241,115 cases in the 7MM.
• Globally, CRC is the third most commonly diagnosed cancer in males and the second in females, with 1.8 million new cases and almost 861,000 deaths in 2018, according to the World Health Organization GLOBOCAN database.
• In the year 2021, the total incident cases of Colorectal Cancer were around 539,240 cases in the 7MM, which might increase by 2032.
• In the 7MM, the highest number of incident cases of Colorectal Cancer was observed in the US, with approximately 148,940 cases in the year 2021.
• In the year 2021, the total incident cases of metastatic colorectal cancer were around 241,120 cases in the 7MM.
• In the EU-5 countries, the incident cases of metastatic colorectal cancer were around 108,220 cases in the year 2021, with the highest cases being reported in Germany.

Discover How Metastatic Colorectal Cancer Market Will Grow by 2032:
https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer (mCRC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Colorectal Cancer therapies in the market. It also provides a detailed assessment of the Metastatic Colorectal Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Metastatic Colorectal Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Metastatic Colorectal Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Metastatic Colorectal Cancer Epidemiology Segmented as -
• Incident Cases of Colorectal Cancer (CRC) in the 7MM [2019-2032]
• Incident Cases of Metastatic Colorectal Cancer (mCRC) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Metastatic Colorectal Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer (mCRC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Colorectal Cancer market or expected to be launched during the study period. The analysis covers the market share by Metastatic Colorectal Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Metastatic Colorectal Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Colorectal Cancer (mCRC) Therapeutics Outlook
The treatment plan for mCRC may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care is also important to help relieve symptoms and side effects.

The first, second, and third-line treatment regimen of mCRC involves the use of multi-agent chemotherapy (i.e. Folfox, Folfiri, Capeox), anti-angiogenesis therapy with or without chemotherapy, epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, and others with or without chemotherapy. Along with these therapies, Opdivo, with or without Yervoy, and Braftovi, in combination with Erbitux, are approved for the treatment of mCRC patients as the only second and third-line therapies, while Keytruda is approved as the only first-line therapy of mCRC.

Leading Companies in the Metastatic Colorectal Cancer (mCRC) Therapeutics Market Include
Merck, Alexion Pharmaceuticals, GlaxoSmithKline (GSK), Array BioPharma/ Pfizer + Pfizer, Eli Lilly, Taiho Oncology, Bristol-Myers Squibb, Amgen, Mirati Therapeutics + Merck, Hutchison Medipharma, G1 Therapeutics, Amgen, AB Science, Incyte Corporation, Daiichi Sankyo/AstraZeneca, Merck/Janssen, Cardiff oncology, EpicentRx, Merck/Eisai, Seagen + Roche, NeoImmuneTech (Genexine) + Merck, Black Diamond Therapeutics, Gilead Sciences + Eli Lilly and Company, Ludwig Institute for Cancer Research + Targovax ASA, and others.

Emerging and Marketed Metastatic Colorectal Cancer (mCRC) Therapies Covered in the Report Include
• Keytruda (pembrolizumab) injection: Merck
• Stivarga (Regorafenib): Alexion Pharmaceuticals
• Jemperli (dostarlimab): GlaxoSmithKline (GSK)
• Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib): Array BioPharma/ Pfizer + Pfizer
• Adagrasib (MRTX849) + cetuximab: Mirati Therapeutics + Merck
• MK-4280A (favezelimab and pembrolizumab): Merck
• Elunate (fruquintinib/HMPL-013): Hutchison Medipharma
• Corsela (trilaciclib): G1 Therapeutics
• Modufolin (arfolitixorin): Isofol Medical
And Many More

Learn More About the Emerging Therapies & Key Companies in the Metastatic Colorectal Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Colorectal Cancer Competitive Intelligence Analysis
4. Metastatic Colorectal Cancer Market Overview at a Glance
5. Metastatic Colorectal Cancer Background and Overview
6. Metastatic Colorectal Cancer Patient Journey
7. Metastatic Colorectal Cancer Epidemiology and Patient Population
8. Metastatic Colorectal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Colorectal Cancer Unmet Needs
10. Key Endpoints of Metastatic Colorectal Cancer Treatment
11. Metastatic Colorectal Cancer Marketed Products
12. Metastatic Colorectal Cancer Emerging Therapies
13. Metastatic Colorectal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Colorectal Cancer Market Outlook (7 major markets)
16. Metastatic Colorectal Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Colorectal Cancer Market.
18. Metastatic Colorectal Cancer Market Drivers
19. Metastatic Colorectal Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Mucinous Cystic Neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market

Overt Hepatic Encephalopathy Market
https://www.delveinsight.com/report-store/overt-hepatic-encephalopathy-market

Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report

Lateral Epicondylitis (Tennis Elbow) Disease Market
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market

Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market

Neurovascular Thrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market

Neurothrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market

Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market

Genital Herpes Market
https://www.delveinsight.com/report-store/genital-herpes-market-forecast

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Neurotrophic Keratopathy Market
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market

Oncolytic Virus Cancer Therapy Market
https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market

Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market

Advanced Wound Care (AWC) Market
https://www.delveinsight.com/report-store/advanced-wound-care-market

Opioid-related Disorders Market
https://www.delveinsight.com/report-store/opioid-related-disorders-market

Ankylosing Spondylitis (AS) Market
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market

Chronic Insomnia Market
https://www.delveinsight.com/report-store/chronic-insomnia-market

Microscopic Polyangiitis (MPA) Market
https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market

Esophageal Squamous Carcinoma Market
https://www.delveinsight.com/report-store/esophageal-squamous-carcinoma-market

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market

Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market

Idiopathic Interstitial Pneumonia Market
https://www.delveinsight.com/report-store/idiopathic-interstitial-pneumonia-market

Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market

Dyslipidemia Market
https://www.delveinsight.com/report-store/dyslipidemia-market

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market

Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market

Alpha-Antitrypsin Deficiency Market
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.